Target Audience
A CME/CE activity for Primary Care Physicians, Registered Nurses, Nurse Practioners, Physician Assistants and other Allied Health professionals.
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the sponsorship of National Jewish Medical and Research Center's Office of Professional Education. National Jewish Medical and Research Center is accredited by the ACCME to provide continuing medical education for physicians.
National Jewish Medical and Research Center designates this educational activity for a maximum of 3 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Goals and Objectives
After completing this review of primary care management of chronic obstructive pulmonary disease (COPD), physicians should be able to:
- Summarize the epidemiology and etiology of COPD;
- Understand the role of tobacco smoke as a primary pathogenetic agent in COPD;
- Assure that smoking/non-smoking status and smoking history are obtained for all patients;
- Offer smoking cessation information, counseling, and/or referral to all patients who indicate a willingness to quit smoking;
- Outline information and studies needed to confirm a diagnosis of COPD;
- Relate classification (staging) of COPD to options for treatment;
- Understand rationale for non-pharmacologic treatments for COPD;
- Describe appropriate uses of bronchodilators, corticosteroids, and other pharmacologic agents in treatment of COPD;
- Recognize patients at risk for COPD exacerbation, and recognize appropriate uses of maintenance therapy, rescue therapy, and hospitalization/ICU admission; and,
- Understand importance of psychological, emotional, and behavioral issues that increase the burden of COPD on the patient, family, and on health-care providers.
Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease that (1) afflicts a substantial percentage of the U.S. population, (2) is increasing in prevalence, due in part to a rise in prevalence among women, (3) is one of the more costly chronic diseases in dollars, use of health-care resources, and physical impairment, and (4) cannot be cured but can be prevented and, increasingly, effectively managed.
The patient with COPD is usually seen first in a primary care setting. Diagnosis, differential diagnosis (e.g., asthma), and treatment are commonly undertaken by the primary care physician. Prevention of COPD by smoking cessation counseling should be a mandated goal in every primary care practice. Management of severe COPD may require referral to a pulmonologist or tertiary respiratory disease center. Referral guidelines are available to assist the primary care physician in obtaining optimum management of the patient with severe or exacerbating COPD.
Participating Faculty
Ronald Balkissoon, MD, FRCRC, DIH, MSc
Associate Professor of Medicine
National Jewish Medical and Research Center
Associate Professor, Department of Medicine
and the Department of Biometrics and Preventive Medicine
University of Colorado Health Sciences Center
Barry Make, MD
Co-Director, COPD Program
Director, Pulmonary Rehabilitation
National Jewish Medical and Research Center
Professor of Medicine
Division of Pulmonary Sciences and Critical Medicine
University of Colorado School of Medicine
James T. Good, MD, FACP, FCCP
Professor of Medicine
Director of Medical Outpatient Services in the Pulmonary Division
National Jewish Medical and Research Center
Liesel Dyar, PsyD
Clinical Health Psychologist
National Jewish Medical and Research Center.
Russell Bowler, MD, PhD
Assistant Professor
Director, COPD Clinic
National Jewish Medical and Research Center
Associate Professor
Department of Medicine
University of Colorado Health Sciences Center
William Janssen, MD
Assistant Professor
National Jewish Medical and Research Center
University of Colorado Health Sciences Center
Faculty Disclosure
All faculty in a position to control of the content of this activity are expected to disclose any or no significant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties.
Significant financial interest is defined as receiving, or in the past twelve months having received, a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit.
KEY
± Grant Support
^ Consultant
~ Speaker's Bureau
> Other
Ronald Balkissoon, MD, FRCRC, DIH, MSc
^~ AstraZeneca
~ Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis
Russell Bowler, MD, PhD
Has no significant financial interest to report.
Liesel Dyar, PsyD
Has no significant financial interest to report.
James T. Good, MD, FACP, FCCP
Has no significant financial interest to report.
William Janssen, MD
Has no significant financial interest to report.
Barry Make, MD
^ Altana, AstraZeneca, Forest, Schering-Plough
^ ~ > Boehringer-Ingelheim, GlaxoSmithKline, Pfizer, Inc.
This course is presented to you by National Jewish Medical and Research Center, Denver, CO USA.
|
Monograph